Healthcare provider profile · identity verified

Saw K. Hlaing, MD

Internal Medicine · FRESNO, CA · NPI 1417035247

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	430	112
Amlodipine Besylate	Amlodipine Besylate	229	59
Pantoprazole Sodium	Pantoprazole Sodium	200	55
Metoprolol Succinate	Metoprolol Succinate	177	36
Famotidine	Famotidine	175	37
Gabapentin	Gabapentin	173	54
Lisinopril	Lisinopril	152	48
Levothyroxine Sodium	Levothyroxine Sodium	150	47
Omeprazole	Omeprazole	143	20
Furosemide	Furosemide	136	44
Losartan Potassium	Losartan Potassium	133	42
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	132	41
Isosorbide Mononitrate Er	Isosorbide Mononitrate	131	20
Jardiance	Empagliflozin	122	23
Metoprolol Tartrate	Metoprolol Tartrate	121	23
Bumetanide	Bumetanide	114	30
Hydralazine Hcl	Hydralazine Hcl	108	30
Potassium Chloride	Potassium Chloride	105	27
Glipizide	Glipizide	95	19
Eliquis	Apixaban	92	14
Tamsulosin Hcl	Tamsulosin Hcl	89	31
Duloxetine Hcl	Duloxetine Hcl	84	13
Albuterol Sulfate Hfa	Albuterol Sulfate	79	42
Donepezil Hcl	Donepezil Hcl	77	14
Metformin Hcl	Metformin Hcl	76	15
Amiodarone Hcl	Amiodarone Hcl	68	18
Montelukast Sodium	Montelukast Sodium	66	16
Clopidogrel	Clopidogrel Bisulfate	63	32
Terazosin Hcl	Terazosin Hcl	60	suppressed
Mirtazapine	Mirtazapine	57	22
Pradaxa	Dabigatran Etexilate Mesylate	57	22
Fluticasone Propionate	Fluticasone Propionate	55	25
Trospium Chloride	Trospium Chloride	52	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	45	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	42	19
Allopurinol	Allopurinol	40	15
Humulin R	Insulin Regular, Human	39	12
Carvedilol	Carvedilol	36	18
Alendronate Sodium	Alendronate Sodium	35	20
Diltiazem 12hr Er	Diltiazem Hcl	35	suppressed
Tizanidine Hcl	Tizanidine Hcl	33	15
Baclofen	Baclofen	31	suppressed
Roflumilast	Roflumilast	31	suppressed
Xifaxan	Rifaximin	31	suppressed
Midodrine Hcl	Midodrine Hcl	30	suppressed
Sertraline Hcl	Sertraline Hcl	28	14
Spiriva Respimat	Tiotropium Bromide	28	13
Oxycodone Hcl	Oxycodone Hcl	25	18
Lovastatin	Lovastatin	24	suppressed
Spironolactone	Spironolactone	24	13
Atenolol	Atenolol	23	13
Ondansetron Odt	Ondansetron	23	11
Pregabalin	Pregabalin	23	suppressed
Latanoprost	Latanoprost	21	suppressed
Lactulose	Lactulose	20	suppressed
Prednisone	Prednisone	19	12
Cefadroxil	Cefadroxil	18	16
Finasteride	Finasteride	18	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	18	suppressed
Tramadol Hcl	Tramadol Hcl	18	suppressed
Colchicine	Colchicine	17	suppressed
Levetiracetam	Levetiracetam	17	suppressed
Nystatin	Nystatin	17	11
Simvastatin	Simvastatin	17	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	17	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	17	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	16	suppressed
Humulin N	Insulin Nph Human Isophane	15	suppressed
Warfarin Sodium	Warfarin Sodium	15	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Verapamil Er	Verapamil Hcl	14	suppressed
Glucagon Emergency Kit	Glucagon	13	suppressed
Metformin Hcl Er	Metformin Hcl	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Trazodone Hcl	Trazodone Hcl	13	suppressed
Bupropion Hcl	Bupropion Hcl	12	suppressed
Digoxin	Digoxin	12	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Olanzapine	Olanzapine	12	suppressed
Alvesco	Ciclesonide	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Metformin Er Osmotic	Metformin Hcl	11	suppressed
Mupirocin	Mupirocin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error